BofA sees higher gold prices, likely to hit $5,000/oz in 2026
Procept Biorobotics Corp's stock recently reached a 52-week low, trading at 32.07 USD, significantly below its 52-week high of 103.81 USD. This milestone marks a significant downturn for the company, as its stock has experienced a substantial decline over the past year. InvestingPro data shows the company maintains a strong balance sheet with more cash than debt and a healthy current ratio of 9.21. The 1-year change data reveals a sharp decrease of 63.31%, with year-to-date returns down 56.51%, reflecting challenges the company may be facing in the market despite impressive revenue growth of 55.71%. This low point highlights a period of volatility and uncertainty for Procept Biorobotics, as investors and analysts closely watch for any signs of recovery or further decline. Interestingly, InvestingPro analysis suggests the stock may be slightly undervalued at current prices, with analyst targets ranging from $39 to $85. Discover more insights and 6 additional ProTips in the comprehensive Pro Research Report, available for over 1,400 US equities.
In other recent news, PROCEPT BioRobotics reported its third-quarter 2025 earnings, surpassing revenue expectations with $83.3 million, marking a 43% increase from the previous year. The company's earnings per share (EPS) were recorded at -$0.38, slightly better than the anticipated -$0.41. Leerink Partners noted a 3% revenue beat, highlighting U.S. system sales of 57 units, exceeding the consensus expectation of 52 units. Despite the positive revenue performance, Leerink Partners lowered its price target for PROCEPT BioRobotics to $55 from $65, while maintaining an Outperform rating. These developments reflect recent financial activities and analyst assessments surrounding the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.